How to optimize the treatment sequence in Relapsed and Refractory Multiple Myeloma patients

Friday, May 15, 2020
11:30-13:00
Paris, France

Chairs: Mohamad Mohty and Hermann Einsele
First line treatment options and how they impact the following treatment decisions
Thierry Facon
Lenalidomide Relapsed and Refractory Multiple Myeloma patients, one size fits it all? Or The role of Pomalidomide in the treatment of Lenalidomide-refractory multiple myeloma
Maria Vitoria Mateos
AntiCD38 antibody therapy in Lenalidomide-Refractory Multiple Myeloma patients: evidence-based therapy considerations
Philippe Moreau
Health-related quality of life in patients with relapsed/refractory multiple myeloma
Kwee Yong
Audience Discussion
Closing Remarks
Chairs: Mohamad Mohty and Hermann Einsele